Upstream Bio Reports Positive Phase 2 VALIANT Trial Results for Verekitug in Severe Asthma

summarizeSummary

Upstream Bio reported positive Phase 2 VALIANT trial results for verekitug in severe asthma, meeting its primary endpoint with significant reductions in exacerbation rates and a favorable safety profile.

check_boxKey Events

• Phase 2 VALIANT Trial Met Primary Endpoint

  Verekitug demonstrated statistically significant and clinically meaningful reductions in annualized asthma exacerbation rates (AAER) in severe asthma patients, meeting the primary endpoint of the VALIANT study.

• Significant Efficacy Data

  The 100mg q12w dose showed a 56% AAER reduction (p<0.0003), and the 400mg q24w dose showed a 39% AAER reduction (p<0.02). Both doses also delivered clinically meaningful improvements in lung function (FEV1) and exhaled nitric oxide (FeNO).

• Favorable Safety Profile

  Verekitug was generally well tolerated across treatment groups, with a safety profile consistent with prior studies, and overall incidence of treatment-emergent adverse events (TEAEs) was similar across groups.

• Strong Financial Position

  The company reported preliminary unaudited cash, cash equivalents, and short-term investments of approximately $341.5 million as of December 31, 2025, which is expected to fund planned operations through 2027.

auto_awesomeAnalysis

Upstream Bio announced highly positive top-line results from its Phase 2 VALIANT clinical trial for verekitug in severe asthma. The study successfully met its primary endpoint, demonstrating statistically significant and clinically meaningful reductions in annualized asthma exacerbation rates (AAER) across both tested dosing regimens. These results, coupled with improvements in lung function and biomarkers and a consistent safety profile, significantly de-risk the development of verekitug and provide a strong foundation for advancing to Phase 3 trials. The company also reported a solid cash position, extending its operational runway.